+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment of allergic asthma by targeting Janus kinase 3-dependent leukotriene synthesis in mast cells with 4- amino-6,7-dimethoxyquinazoline



Treatment of allergic asthma by targeting Janus kinase 3-dependent leukotriene synthesis in mast cells with 4- amino-6,7-dimethoxyquinazoline



Journal of Pharmacology & Experimental Therapeutics 295(3): 912-926



4-(3',5'-Dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97) is a rationally designed potent inhibitor of Janus kinase (JAK)-3. Treatment of mast cells with WHI-P97 inhibited the translocation of 5-lipoxygenase (5-LO) from the nucleoplasm to the nuclear membrane and consequently 5-LO-dependent leukotriene (LT) synthesis after IgE receptor/FcepsilonRI crosslinking by >90% at low micromolar concentrations. WHI-P97 did not directly inhibit the enzymatic activity of 5-LO, but prevented its translocation to the nuclear membrane without affecting the requisite calcium signal. WHI-P97 was very well tolerated in mice, with no signs of toxicity at dose levels ranging from 5 mug/kg to 50 mg/kg, and LD10 was not reached at a 50 mg/kg dose level when administered as a single i.p. or i.v. bolus dose. Therapeutic WHI-P97 concentrations, which inhibit mast cell leukotriene synthesis in vitro, could easily be achieved in vivo after the i.v. or i.p. administration of a single nontoxic 40 mg/kg bolus dose of WHI-P97. Notably, WHI-P97 showed promising biological activity in a mouse model of allergic asthma at nontoxic dose levels. Treatment of ovalbumin-sensitized mice with WHI-P97 prevented the development of airway hyper-responsiveness to methacholine in a dose-dependent fashion. Furthermore, WHI-P97 inhibited the eosinophil recruitment to the airway lumen after the ovalbumin challenge in a dose-dependent fashion. Further development of WHI-P97 may therefore provide the basis for new and effective treatment as well as prevention programs for allergic asthma in clinical settings.

(PDF emailed within 1 workday: $29.90)

Accession: 035980904

Download citation: RISBibTeXText


Related references

Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3', 5'-dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97). Journal of Pharmacology and Experimental Therapeutics 295(3): 912-926, 2000

Islet allograft rejection is prevented by targeting Janus kinase 3 with 4- -amino-6,7-dimethoxyquinazoline. Diabetes Research & Clinical Practice 50(Suppl 1): S183, 2000

Prevention of development of type 1 diabetes in NOD mice by targeting Janus kinase 3 with 4- -amino-6,7-dimethoxyquinazoline. Diabetes Research & Clinical Practice 50(Suppl 1): S183, 2000

Prevention of islet allograft rejection in diabetic mice by targeting Janus Kinase 3 with 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (JANEX-1). Arzneimittel-Forschung 53(9): 648-654, 2003

Role of Janus kinase-2 in IgE receptor-mediated leukotriene C4 production by mast cells. Biochemical and Biophysical Research Communications 390(3): 786-790, 2009

Pharmacokinetics and in vivo toxicity of Janus kinase 3 inhibitor WHI-P131 -amino-6,7-Dimethoxyquinazoline. Blood 94(10 SUPPL 1 PART 2): 197b, Nov 15, 1999

Janus kinase-3 dependent inflammatory responses in allergic asthma. International Immunopharmacology 10(8): 829-836, 2011

In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 [4-(4'hydroxyphenyl)-amino-6,7- dimethoxyquinazoline. Clinical Cancer Research 5(10): 2954-2962, 1999

Targeting mast cells in endometriosis with janus kinase 3 inhibitor, JANEX-1. American Journal of Reproductive Immunology 58(2): 75-97, 2007

Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis. Journal of Biological Chemistry 274(38): 27028-27038, 1999

CYP1A-mediated metabolism of the Janus kinase-3 inhibitor 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline: Structural basis for inactivation by regioselective O-demethylation. Drug Metabolism and Disposition 30(1): 74-85, 2002

CYP1A-mediated metabolism of the Janus kinase-3 inhibitor 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline: structural basis for inactivation by regioselective O-demethylation. Drug Metabolism and Disposition: the Biological Fate of Chemicals 30(1): 74-85, 2001

Inhibition of the antigen-induced activation of rodent mast cells by putative Janus kinase 3 inhibitors WHI-P131 and WHI-P154 in a Janus kinase 3-independent manner. British Journal of Pharmacology 145(6): 818-828, 2005

Prevention of fatal thromboembolism in mice by selectively targeting Jak 3 kinase in platelets with 4- -amino-6,7-dimethoxyquinazoline. Blood 96(11 Part 1): 273a, November 16, 2000

A specific sphingosine kinase 1 inhibitor attenuates airway hyperresponsiveness and inflammation in a mast cell-dependent murine model of allergic asthma. Journal of Allergy and Clinical Immunology 131(2): 501-11.E1, 2013